BIOMAT Database Logo BIOMAT Database Logo

Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations. 1999

J C Byrd, and G R Devi, and A T de Souza, and R L Jirtle, and R G MacDonald
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska 68198-4525, USA.

The insulin-like growth factor II/mannose 6-phosphate receptor (IGF2R) carries out multiple regulatory and transport functions, and disruption of IGF2R function has been implicated as a mechanism to increase cell proliferation. Several missense IGF2R mutations have been identified in human cancers, including the following amino acid substitutions occurring in the extracytoplasmic domain of the receptor: Cys-1262 --> Ser, Gln-1445 --> His, Gly-1449 --> Val, Gly-1464 --> Glu, and Ile-1572 --> Thr. To determine what effects these mutations have on IGF2R function, mutant and wild-type FLAG epitope-tagged IGF2R constructs lacking the transmembrane and cytoplasmic domains were characterized for binding of insulin-like growth factor (IGF)-II and a mannose 6-phosphate-bearing pseudoglycoprotein termed PMP-BSA (where PMP is pentamannose phosphate and BSA is bovine serum albumin). The Ile-1572 --> Thr mutation eliminated IGF-II binding while not affecting PMP-BSA binding. Gly-1449 --> Val and Cys-1262 --> Ser each showed 30-60% decreases in the number of sites available to bind both (125)I-IGF-II and (125)I-PMP-BSA. In addition, the Gln-1445 --> His mutant underwent a time-dependent loss of IGF-II binding, but not PMP-BSA binding, that was not observed for wild type. In all, four of the five cancer-associated mutants analyzed demonstrated altered ligand binding, providing further evidence that loss of IGF2R function is characteristic of certain cancers.

UI MeSH Term Description Entries
D007335 Insulin-Like Growth Factor II A well-characterized neutral peptide believed to be secreted by the LIVER and to circulate in the BLOOD. It has growth-regulating, insulin-like and mitogenic activities. The growth factor has a major, but not absolute, dependence on SOMATOTROPIN. It is believed to be a major fetal growth factor in contrast to INSULIN-LIKE GROWTH FACTOR I, which is a major growth factor in adults. IGF-II,Multiplication-Stimulating Activity,Somatomedin MSA,IGF-2,Insulin Like Growth Factor II,Insulin-Like Somatomedin Peptide II,Multiplication-Stimulating Factor,Somatomedin A,Factor, Multiplication-Stimulating,Insulin Like Somatomedin Peptide II,Multiplication Stimulating Activity,Multiplication Stimulating Factor
D008360 Mannosephosphates Phosphoric acid esters of mannose.
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D017527 Receptor, IGF Type 2 A receptor that is specific for IGF-II and mannose-6-phosphate. The receptor is a 250-kDa single chain polypeptide which is unrelated in structure to the type 1 IGF receptor (RECEPTOR, IGF TYPE 1) and does not have a tyrosine kinase domain. IGF Type 2 Receptor,IGF-II Receptor,Receptor, IGF-II,Receptor, Insulin-Like Growth Factor II,Receptor, Insulin-Like Growth Factor Type 2,Receptor, Mannose-6-Phosphate,IGF-2 Receptor,Insulin-Like-Growth-Factor II Receptor,Mannose-6-Phosphate Receptor,Receptors, IGF-2,Receptors, Insulin-Like Growth Factor II,IGF 2 Receptor,IGF II Receptor,IGF-2 Receptors,Insulin Like Growth Factor II Receptor,Mannose 6 Phosphate Receptor,Receptor, IGF II,Receptor, IGF-2,Receptor, Insulin Like Growth Factor II,Receptor, Insulin Like Growth Factor Type 2,Receptor, Insulin-Like-Growth-Factor II,Receptor, Mannose 6 Phosphate,Receptors, IGF 2,Receptors, Insulin Like Growth Factor II
D019656 Loss of Heterozygosity The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted. Allelic Loss,Heterozygosity, Loss of,Allelic Losses,Heterozygosity Loss
D020125 Mutation, Missense A mutation in which a codon is mutated to one directing the incorporation of a different amino acid. This substitution may result in an inactive or unstable product. (From A Dictionary of Genetics, King & Stansfield, 5th ed) Missense Mutation,Missense Mutations,Mutations, Missense

Related Publications

J C Byrd, and G R Devi, and A T de Souza, and R L Jirtle, and R G MacDonald
Mechanisms for high affinity mannose 6-phosphate ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor.
June 2000, The Journal of biological chemistry,
J C Byrd, and G R Devi, and A T de Souza, and R L Jirtle, and R G MacDonald
Mannose 6-phosphate/insulin-like growth factor II receptor: distinct binding sites for mannose 6-phosphate and insulin-like growth factor II.
February 1988, Biochemical and biophysical research communications,
J C Byrd, and G R Devi, and A T de Souza, and R L Jirtle, and R G MacDonald
The two mannose 6-phosphate binding sites of the insulin-like growth factor-II/mannose 6-phosphate receptor display different ligand binding properties.
August 1998, The Journal of biological chemistry,
J C Byrd, and G R Devi, and A T de Souza, and R L Jirtle, and R G MacDonald
Mannose 6-phosphate/insulin-like growth factor II-binding proteins in human serum and urine. Their relation to the mannose 6-phosphate/insulin-like growth factor II receptor.
June 1988, The Biochemical journal,
J C Byrd, and G R Devi, and A T de Souza, and R L Jirtle, and R G MacDonald
The bovine mannose 6-phosphate/insulin-like growth factor II receptor. The role of arginine residues in mannose 6-phosphate binding.
March 1993, The Journal of biological chemistry,
J C Byrd, and G R Devi, and A T de Souza, and R L Jirtle, and R G MacDonald
Dimerization of the insulin-like growth factor II/mannose 6-phosphate receptor.
June 2000, The Journal of biological chemistry,
J C Byrd, and G R Devi, and A T de Souza, and R L Jirtle, and R G MacDonald
The rate of internalization of the mannose 6-phosphate/insulin-like growth factor II receptor is enhanced by multivalent ligand binding.
January 1999, The Journal of biological chemistry,
J C Byrd, and G R Devi, and A T de Souza, and R L Jirtle, and R G MacDonald
Insulin-like growth factor-II/mannose 6-phosphate receptor is incapable of activating GTP-binding proteins in response to mannose 6-phosphate, but capable in response to insulin-like growth factor-II.
May 1990, Biochemical and biophysical research communications,
J C Byrd, and G R Devi, and A T de Souza, and R L Jirtle, and R G MacDonald
Beta-galactosidase decreases the binding affinity of the insulin-like-growth-factor-II/mannose-6-phosphate receptor for insulin-like-growth-factor II.
May 1990, European journal of biochemistry,
J C Byrd, and G R Devi, and A T de Souza, and R L Jirtle, and R G MacDonald
High-affinity ligand binding by wild-type/mutant heteromeric complexes of the mannose 6-phosphate/insulin-like growth factor II receptor.
April 2009, The FEBS journal,
Copied contents to your clipboard!